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Abstract
Background: In early pregnancy, increased plasma levels of the endocannabinoid anandamide (AEA) are
associated with miscarriage through mechanisms that might affect the developing placenta or maternal decidua.
Methods: In this study, we compare AEA levels in failed and viable pregnancies with the levels of the
trophoblastic hormones (beta-human chorionic gonadotrophin (beta-hCG), progesterone (P4) and (pregnancy-
associated placental protein-A (PAPP-A)) essential for early pregnancy success and relate that to the expression of
the cannabinoid receptors and enzymes that modulate AEA levels.
Results: The median plasma AEA level in non-viable pregnancies (1.48 nM; n = 20) was higher than in viable
pregnancies (1.21 nM; n = 25; P = 0.013), as were progesterone and beta-hCG levels (41.0 vs 51.5 ng/mL; P = 0.052
for P4 and 28,650 vs 6,560 mIU/L; P = 0.144 for beta-hCG, respectively, but were not statistically significant). Serum
PAPP-A levels in the viable group were approximately 6.8 times lower than those in the non-viable group (1.82 vs
12.25 mg/L; P = 0.071), but again these differences were statistically insignificant. In the spontaneous miscarriage
group, significant correlations between P4 and beta-hCG, P4 and PAPP-A and AEA and PAPP-A levels were
observed. Simultaneously, immunohistochemical distributions of the two main cannabinoid receptors and the AEA-
modifying enzymes, fatty acid amide hydrolase (FAAH) and N-acylphosphatidylethanolamine-phospholipase D
(NAPE-PLD), changed within both the decidua and trophoblast.
Conclusions: The association of higher AEA levels with early pregnancy failure and with beta-hCG and PAPP-A, but
not with progesterone concentrations suggest that plasma AEA levels and pregnancy failure are linked via a
mechanism that may involve trophoblastic beta-hCG, and PAPP-A, but not, progesterone production. Although the
trophoblast, decidua and embryo contain receptors for AEA, the main AEA target in early pregnancy failure
remains unknown.
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Background
Successful implantation and maintenance of pregnancy
occurs through a complex interaction between fetal
and maternal tissues that involves several factors
including the hormones estrogen and progesterone
[1,2], human chorionic gonadotrophin [3-6], inhibin
[5,7,8], pregnancy associated plasma protein (PAPP)-A
[6,8,9], and a balance between type 1 T-helper (Th1)
and type 2 T-helper (Th2) cytokines [10]. Although a
unique immunological interplay is essential for the
lack of rejection of the fetus by the mother, little is
known about the precise factors responsible for the
synchronous development of the embryo and the
endometrium to ensure timely and successful implan-
tation. Recent evidence from the murine model [11],
and to a lesser extent, women undergoing IVF [12,13]
has implicated the endocannabinoid system and in par-
ticular, the endogenous ligand, anandamide (AEA) in
these processes. The endocannabinoid system consists
of several natural ligands; i.e. AEA, 2-arachidonyl-
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mitoylethanolamine (PEA) and virodhamine, their cog-
nate and related receptors; i.e. cannabinoid receptors 1
(CB1) and 2 (CB2), the orphan receptor G-protein
coupled receptor 55 (GPR55), peroxisome proliferator-
activated receptor-a (PPAR-a)a n dt h eC a
2+ channel
vanilloid receptor 1 (TRPV1), and the enzymes that
modulate the ligand concentrations; i.e. N-acyl trans-
ferase (NAT), N-acylphosphatidylethanolamine-phos-
pholipase D (NAPE-PLD), fatty acid amide hydrolase
(FAAH), diacylglycerol lipase (DAGL) and monoacyl-
glycerol lipase (MAGL) [14,15].
Anandamide, originally isolated and characterised in
1992 [16], and four years after the cannabinoid recep-
tors were identified [17], has been shown to be a key
molecule that is important to the hormone-cytokine dia-
logue between the blastocyst and the endometrium in
experimental animals, ensuring that the latter is ‘tuned’
to receive the former [11,18]. In such animals, altera-
tions in the levels of AEA at the endometrium have
resulted in failed implantation and/or failure to maintain
pregnancy [19], suggesting that a decrease in the activa-
tion pathways for anandamide mainly via its G-protein-
coupled receptor CB1 is essential for early pregnancy
success. Indeed, experiments have demonstrated that
female CB1 receptor knock-out mouse models not only
e x h i b i ti m p a i r e df e r t i l i t yb u ta l s os u f f e rf r o mi m p a i r e d
oviductal transport with resultant ectopic pregnancies
[20], indicating that AEA signalling through the CB1
receptor is important in this aspect of mouse fertility.
In humans, such evidence at the level of the endome-
trium is lacking but the levels of the enzyme fatty acid
amide hydrolase (FAAH), which is responsible for the
catabolism of AEA into ethanolamine and arachidonic
acid [21-26], measured at 6-8 weeks in asymptomatic
pregnancies have been shown to be significantly lower
in those that eventually spontaneously miscarry [13]. In
addition, it has also been demonstrated that the plasma
AEA levels at 6 weeks in women who had undergone
IVF were significantly lower in those who achieved a
viable pregnancy than in those who did not [12,13].
We have also shown that plasma levels of AEA in
those presenting with a threatened miscarriage and an
ultrasound confirmed viable pregnancy are significantly
higher in those who subsequently spontaneously miscar-
ried, compared to those who had live births [27]. All
those with plasma AEA levels above 2 nM subsequently
miscarried while 94% of those with plasma AEA levels
<2 nM had live births. Whether these differences are
similar in those who had already miscarried or had non-
viable pregnancies is yet to be investigated.
Since progesterone, human chorionic gonadotrophin
and pregnancy associated plasma protein (PAPP)-A, a
trophoblast-derived protease that degrades the insulin-
like growth factor binding proteins 4 and 5 [28] are
involved in the regulatory processes responsible for the
early maintenance of pregnancy, and progesterone has
also been suggested to be involved in the regulation of
AEA [29], we set out to examine whether there is (a) a
difference in AEA levels in pregnancies which are con-
firmed to be either non-viable or viable and, (b) a rela-
tionship, between plasma AEA, serum progesterone
(P4), human chorionic gonadotrophin (b-hCG) and
PAPP-A in these two groups. Furthermore, we exam-
ined the expression and distribution of cannabinoid
receptors 1 and 2 and the AEA metabolizing enzymes,
FAAH and the key enzyme involved in AEA synthesis,
NAPE-PLD, in the placenta and decidua of women hav-
ing a spontaneous miscarriage and those undergoing
induced abortions with an anti-progestin (mifepristone;
RU486) and a prostaglandin (misoprostol) in compari-
son to the expression levels in normal pregnancy.
Methods
Patients and study design
This was a prospective cohort study of women attending
the Early Pregnancy Assessment Unit (EPAU) of the
University Hospitals of Leicester NHS Trust at the Lei-
cester Royal Infirmary. All subjects gave signed,
informed consent to take part in the study, which had
approval of the Leicestershire and Rutland Research
Ethics Committee. The research was sponsored by the
local R&D office of the University Hospitals of Leicester
NHS Trust.
A power analysis based on previous work of the Endo-
cannabinoid Research Group and that of other pub-
lished data of viable and non-viable pregnancies [13],
with a =0 . 0 5a n db = 0.8 showed that a minimum of 6
subjects was required in both the miscarriage and on-
going pregnancy groups to allow a 40% change in
plasma AEA levels to be observed with 80% power.
Recruitment therefore continued until this minimum
number was exceeded.
Asymptomatic women at 6-12 weeks amenorrhoea,
presenting to the EPAU for a reassurance ultrasound
because of a previous miscarriage, were recruited into
the study prior to the ultrasound scan used to determine
viability. For the viable pregnancies, only those with sin-
gleton pregnancies were included, because we were
unsure of how multiple pregnancies would affect results.
Blood samples were collected from the antecubital vein
for the measurement of plasma AEA and various hor-
mones. A total of 14 mL of blood was collected; 4 mL
into an EDTA tube for AEA quantification and 10 mL
into a plain tube for serum P4, b-hCG and PAPP-A
measurement. The tubes containing the blood were
placed on ice and transported to the research laboratory
where plasma and sera were separated. Serum was
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plasma was processed for AEA quantification as
described below.
For the immunohistochemical studies, products of
conception were collected between 7 and 12 weeks
gestation from women undergoing surgical termination
(suction curettage; n = 60) and between 7 and 9 weeks
for medical termination (600 mg mifepristone followed
36-48 hours later with 800-1200 mg misoprostol, n =
2 5 )o fp r e g n a n c y .A l lh a da nu l t r a s o u n ds c a ne x a m i n a -
tion to accurately date the pregnancies before termina-
tion as per the standard practice in the gynaecology
unit. Samples were also collected from 16 spontaneous
miscarriages, whose dates were determined by ultra-
sound scan. Collected tissues were transported on ice to
the laboratory, where blood was washed away with ster-
ile PBS and pieces of trophoblast and decidua dissected
free with the aid of a dissecting microscope. Each piece
was fixed in 10% neutral-buffered formalin for 4 days,
dehydrated through 70% and 99% industrial methylated
spirits (IMS), cleared with two changes of xylene and
finally embedded in paraffin wax. This was performed in
a LEICA ASP3000 automated vacuum tissue processor.
Archival term placental tissues from women undergoing
elective Caesarean section and full thickness uterine
biopsies from the normal menstrual cycle acted as posi-
tive controls [30,31].
Measurement of AEA
Plasma AEA was extracted using a modification of the
method we previously described [32]. Briefly, the EDTA
tube containing 4 mL of blood was immediately placed
on ice and processed within 2 hours. After centrifuga-
tion at 1200 × g for 30 min at 22°C, 2 mL of plasma
was transferred to a 7 mL glass Kimble scintillation vial
(Fisher Scientific, Loughborough, UK) and 2.5 pmol of
deuterium-labelled AEA (AEA-d8; Cayman Chemicals,
Ann Arbor, MI, USA) was added. Plasma proteins were
then precipitated by thoroughly mixing this mixture
with an equal volume of ice-cold acetone followed by
centrifugation at 1200 × g for 10 min at 22°C. The
supernatant was transferred to a clean Kimble vial and
subjected to a gentle stream of nitrogen gas for 40 min
to evaporate the acetone. Lipid extraction was achieved
by adding methanol:chloroform (1:2 vol; 2 mL) followed
by centrifugation at 1200 × g for 10 min at 22°C. The
lower chloroform layer was then recovered, dried under
nitrogen gas and reconstituted in 80µl HPLC-grade
acetonitrile. The reconstituted mixture was then injected
into an Acquity UPLC in line with a Quattro Premier
mass spectrometer (Waters Ltd., Elstree, UK) for ultra-
high performance liquid chromatography-tandem mass
spectrometry (UPLC-MS/MS) and measured as
described [33].
All solvents and ammonium acetate used were of
HPLC grade (Fisher Scientific, Loughborough, UK) and
HPLC grade water was obtained using a water purifica-
tion system (Maxima ELGA, ELGA, High Wycombe,
UK).
Hormone assays
Serum b-hCG and P4 were measured by the Biochemis-
try Department of the University Hospitals of Leicester
NHS Trust using the ADVIA Centaur Immunoassay
System (Bayer HealthCare LLC, Diagnostics Division;
T a r r y t o w n ,N Y ,U S A ) .S e r u mb-hCG was quantified
using the ADVIA Centaur total b-hCG two-side sand-
wich immunoassay (Bayer HealthCare LLC, Diagnostics
Division; Tarrytown, NY, USA) with a detection range
of 2 mIU/mL to 1000 mIU/mL. If a level of >1000 mIU/
mL was found, a dilution step was preformed and the
assay repeated, allowing up to 100,000 mIU/mL to be
detected. The intra- and the inter-assay coefficients of
variation were 2.8%, and 2.9% respectively. For serum
P4 measurement, the ADVIA Centaur progesterone
competitive immunoassay using direct chemilumines-
cence (Bayer HealthCare LLC, Diagnostics Division;
Tarrytown, NY, USA) was used with a detection range
of 0.48 ng/mL to 190.8 ng/mL with intra- and inter-
assay coefficient of variation of 5.3%, and 3.6%
respectively.
Serum PAPP-A was measured using a commercially
available ELISA kit (Gamma S.A., Liege, Belgium)
according to the manufacturer’s instructions with absor-
bance at 625 nm and 420 nm to determine the signal
intensities of the product and background, respectively.
The relative light intensities were measured on an
Ascent Multiscan ELISA plate reader (Labsystems, Hel-
sinki, Finland). The level of detection was 2-300 mg/L,
and the inter- and intra-assay co-efficients of variation
were 2.9% and 5.4%, respectively.
Immunohistochemistry
A n t i - C B 1a n da n t i - C B 2r a b b i tp o l y c l o n a la n t i b o d i e s
were obtained from Sigma-Aldrich Ltd. (Poole, Dorset,
UK), whilst anti-FAAH rabbit polyclonal antibody was
obtained from Alpha Diagnostics International, Inc.,
(San Antonio, TX) and anti-NAPE-PLD polyclonal anti-
bodies were from Cayman Chemical Corp. (Ann Arbor,
MI). Microwave antigen retrieval [34] was performed for
the CB1, CB2 and NAPE-PLD studies as previously
described [31,35,36], but was not required for the FAAH
studies, because visual inspection of the staining intensi-
ties of representative samples with and without antigen
retrieval were identical. The secondary goat anti-rabbit
horseradish peroxidise conjugates were from Dako
(Glostrup, Denmark), and the tyramide amplification
and detection system was from PerkinElmer LAS
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system (ABC Elite; Vector Laboratories, Peterborough,
UK) was used in conjunction with 3,3’-diaminobenzidine
(Vector Laboratories) to detect the presence of immu-
noreactive complexes for the anti-CB2, anti-FAAH and
anti-NAPE-PLD antibodies, whereas the tyramide ampli-
fication system was substituted for ABC Elite for the
detection of anti-CB1 complexes. The anti-FAAH anti-
bodies were used at an optimal dilution of 1:2000 in
PBS [137 mM NaCl, 9.2 mM Na2HPO4, and 1.46 mM
KH2PO4 (pH 7.6)], whilst CB1 at 1:4000, CB2 at 1:500
and NAPE-PLD at 1:200 dilutions were created in TBS
[500 mM Tris, 1.5 M NaCl (pH 7.6)]. For each antibody
used, negative controls were performed using the same
concentrations of rabbit IgG (for CB1, CB2 and NAPE-
PLD; Vector Laboratories) and normal rabbit serum (for
FAAH; Dako, Glostrup, Denmark). Sections were lightly
counterstained with Mayer’s Haematoxylin (Sigma-
Aldrich Ltd., Poole, Dorset, UK), dehydrated through
graded alcohols, cleared twice in xylene, and mounted
in DPX mountant (BDH, Poole, Dorset, UK). To ensure
consistency for histomorphometric analyses, all slides
(60 surgical terminations, 25 medical terminations and
16 spontaneous miscarriage samples) were processed
simultaneously in a single run for each antibody and
both positive and negative control tissues compared
with previous data [30,31].
Histomorphometric analyses
The pattern of distribution o ft h ep o s i t i v e l ys t a i n e d
cells was recorded as being absent (-), present (+),
absent in some samples but present in others (-/+) or
more intense (++) in the various cellular compart-
ments of the first trimester placenta (cytotrophoblast,
syncytiotrophoblast and mesenchymal core) and in the
decidua for the entire dataset. The number of posi-
tively stained cells per field was assessed by the cap-
ture of 10 randomly selected fields per slide at 400×
magnification [37] for 10 samples of surgical termina-
tions, 10 medical abortions and 10 spontaneous mis-
carriages. The samples were matched for gestational
age and were all from weeks 7 and 8 of gestation.
Images were captured using an Axioplan microscope
(Carl Zeiss, Herts. UK) and a DXC-151P colour video
camera (Sony CCD/RGB) at the same setting with the
light levels set at 6400K in the presence of daylight
and neutral density filters. Immunostaining levels in
the trophoblast layer (cytotrophoblast and syncytiotro-
phoblast) and in the mesenchymal core of the placenta
and the entire decidua were obtained separately using
an unbiased histoscore method inside the pixel count
algorithm (version 9) contained within the Image-
scope
® software package (Aperio Technologies Inc.,
Vista, CA, USA). Weakly stained areas were weighted
100, stained areas 200 and strong staining weighted
300; unstained areas and non-stained areas were
weighted 0. Unstained sections were used as negative
controls and sections treated with IgG/serum instead
of immunised antibody/serum used for the baseline
(non-stained) staining levels.
Statistical analysis
Statistical analysis of the data was performed using
GraphPad Prism version 5.00 for Windows (GraphPad
Software, San Diego California USA, [38]). Data that did
not follow a Gaussian distribution are expressed as med-
ians and inter-quartile ranges (IQR) where appropriate,
and comparisons between groups performed using
Mann-Whitney U-test. Correlations between hormone
measurements were made using Spearman’s correlation.
The histomorphometric data were normally distributed
and so comparisons were made using one-way ANOVA
with Bonferroni’s ad hoc post-test. The level of signifi-
cance was set at P<0.05.
Results
Hormone and anandamide measurements
A total of 45 women were recruited; 25 with viable
pregnancies (viable group) and 20 with non-viable preg-
nancies (non-viable group). There were no differences in
the age or BMI between the two groups, as shown in
Table 1. The median plasma AEA levels in the non-
viable group (1.48 nM) were significantly higher than
those in the viable group (1.21 nM) at the time of ultra-
sound scan (P = 0.013).
Although serum P4 levels were lower in the non-
viable (41 nmol/L) compared to the viable (51.5 ng/mL)
group, this difference was not statistically different (P =
0.052). Similarly, although the levels of b-hCG were
lower in the non-viable group (6560 mU/mL) compared
to the viable group (28650 mU/mL), this also did not
reach statistical significance (P =0 . 1 4 4 ) .T h em e d i a n
serum PAPP-A levels in the non-viable group (12.25
mg/L) were approximately seven times those in the
viable group (1.82 mg/L), but due to the large range of
PAPP-A values obtained, this also was not statistically
significant (P = 0.071).
The inter-relationship between plasma AEA levels and
the levels of the hormones measured are shown in
Table 2. There were no statistically significant correla-
tions between plasma AEA levels and serum progester-
one (r = 0.017; P = 0.926), AEA and b-hCG (r=-0.258, P
= 0.162) and between AEA and PAPP-A (r = 0.35, P =
0.086) in the 45 patients. There was, however, a statisti-
cally significant negative correlation between plasma
AEA levels and the length of gestation (r=-0.327, P =
0.028). There were statistically significant correlations
between b-hCG and progesterone (r = 0.576; P = 0.001),
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and between PAPP-A and b-hCG (r = 0.512, P = 0.025).
A further and separate analysis of the relationships
between plasma AEA levels and PAPP-A, b-hCG and P4
in the viable and non-viable groups was undertaken
(Table 3). In the viable group, there was a negative cor-
relation between b-hCG and plasma AEA levels (r =
-0.466, P = 0.051), although this did not achieve statisti-
cal significance it was close to our cut-off of P<0.05.
T h e r ew e r ea l s on e g a t i v eb u ts t a t i s t i c a l l yi n s i g n i f i c a n t
relationships between P4 and AEA and between PAPP-
A and AEA (P>0.05). In the non-viable group, there was
a statistically significant positive correlation between P4
and b-hCG (r = 0.739, P = 0.004), P4 and PAPP-A (r =
1.00, P<0.0001) and between AEA and PAPP-A (r =
0.697, P = 0.025). As expected b-hCG had a statistically
significant positive correlation with gestation (r = 0.750,
P = 0.003). Plasma AEA levels also had a negative corre-
lation with gestational age (r=-0.475; P =0 . 0 3 5 ) .A l lo f
the other relationships were not statistically significant.
Cannabinoid receptor and AEA modifying enzyme
expression in the trophoblast
T h ee x p r e s s i o np a t t e r n sf o rC B 1 ,C B 2 ,N A P E - P L Da n d
FAAH (Table 4) in the trophoblast of surgical termina-
tions were similar to that reported [39-41] with immu-
noreactive CB1 visible in the syncytiotrophoblast and
cytotrophoblast layers, in the mesenchymal core and the
endothelial cells of the blood vessels but not in fetal
blood cells or infiltrating maternal plasma cells nor in
the vascular smooth muscle cells (Figure 1). In tissues
from the surgical terminations, CB1 immunoreactivity in
the syncytiotrophoblast layer diminished in intensity
with advancing gestation, but did not disappear at gesta-
tion weeks 10 to 12, as previously reported (41; Figure
2).
Like CB1 expression, CB2 immunoreactivity of surgi-
cal terminations was detected in both the syncytiotro-
phoblast and cytotrophoblast layers, in the mesenchymal
core and the endothelial cells of the blood vessels but
not in fetal blood cells or infiltrating maternal plasma
cells nor in the vascular smooth muscle cells (Figure 1)
and the intensity of CB2 immunoreactivity in the syncy-
tiotrophoblast remained constant throughout this gesta-
tional period and through various stages of the first
trimester (Figure 3), in contrast to the immunoreactive
staining patterns for CB1.
Immunoreactive NAPE-PLD was detected in cells that
formed the cytotrophoblast layer and the occasional syn-
cytiotrophoblast cell and was primarily identified to be
present in the nuclei of immunopositive cells (Figure 1).
NAPE-PLD immunoreactivity was occasionally observed
in the nuclei of the mesenchymal core of the developing
villi, but essentially this tissue was negative for NAPE-
PLD immunoreactivity (Figure 1). NAPE-PLD immunor-
eactivity in the cytotrophoblast layer of surgical termina-
tions remained constant throughout the first trimester
(Figure 4).
Table 2 Spearman rank correlations between serum hormone and plasma AEA levels in women within the 1
st
trimester of pregnancy.
All samples P4 b-hCG PAPP-A AEA
r-values P-values n r-values P-values n r-values P-values n r-values P-values n
b-hCG 0.576 0.001 31
PAPP-A 0.506 0.027 19 0.512 0.025 19
AEA 0.017 0.926 31 -0.258 0.162 31 0.351 0.086 25
Gestation 0.045 0.809 31 0.338 0.063 31 -0.192 0.337 27 -0.327 0.028 45
Progesterone (P4) was measured in ng/mL, b-hCG was measured in mIU/mL, PAPP-A was measured in mg/L, AEA was measured in nM and gestation was
measured in weeks. The Spearman co-efficients (r) were calculated using GraphPad Prism software and significant correlations are in bold. The number of
samples (n) is given for each correlation.
Table 1 Patient Demographics and Hormonal Measurements
Parameter Viable Pregnancy
(N = 25)
Non-Viable Pregnancy
(N = 20)
Significance
Age 29 (23-34) 27 (23-29.5) P = 0.34
BMI (kg/m
2) 23 (22-26) 24.5 (21.3-26) P = 0.87
AEA (nM) 1.20 (0.92-1.39) 1.48 (1.01-2.34) P = 0.013
P4 (ng/mL) 51.5 (42-63.5) 41.0 (9.5-65.0) P = 0.052
b-hCG (mIU/mL) 28650 (14172-38707) 6560 (386-49254) P = 0.144
PAPP-A (mg/L) 1.82 (1.56-5.73) 12.25 (1.99-19.63) P = 0.071
Age, body mass index (BMI), plasma AEA levels, serum progesterone (P4), b-hCG and PAPP-A levels are all show as median and (IQR). N = the number of patients
in each group. Significance was calculated using Mann-Whitney U-test. Significant differences between viable and non-viable pregnancies are shown with a bold
P-value.
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noted predominantly throughout the cytoplasm of cells
with some nuclear staining (Figure 1), in keeping with
the membranous and intracytoplasmic vesicular localiza-
tion of FAAH, except in extravillous trophoblasts where
intense nuclear staining was often observed. This was
similar to that observed in the invasive trophoblasts of
recurrent miscarriages [39]. Cytoplasmic/membranous
FAAH protein was observed in both the cytotrophoblast
and syncytiotrophoblast layers and the mesenchymal
Table 3 Spearman rank correlations between serum hormone and plasma AEA levels in women within the 1
st
trimester of pregnancy with viable and non-viable pregnancies.
P4 b-hCG PAPP-A AEA
r-values P-values n r-values P-values n r-values P-values n r-values P-values n
Viable Pregnancies
b-hCG 0.391 0.109 18
PAPP-A 0.266 0.404 12 0.427 0.167 12
AEA -0.247 0.323 18 -0.466 0.051 18 -0.004 0.990 15
Gestation -0.086 0.735 18 0.386 0.114 18 0.156 0.579 15 -0.246 0.236 25
Non-viable Pregnancies
b-hCG 0.739 0.004 13
PAPP-A 1.000 <0.0001 4 0.300 0.624 5
AEA 0.401 0.175 13 0.052 0.865 13 0.697 0.025 10
Gestation 0.490 0.089 13 0.750 0.003 13 -0.532 0.114 10 -0.475 0.035 20
Progesterone (P4) was measured in ng/mL, b-hCG was measured in mIU/mL, PAPP-A was measured in mg/L, AEA was measured in nM and gestation was
measured in weeks. The Spearman co-efficients (r) were calculated using GraphPad Prism software and significant correlations are in bold. The number of
samples (n) is given for each correlation.
Table 4 Immunohistochemical localisation and staining intensities of the various components of the endocannabinoid
system in the first trimester trophoblast and decidua.
Antigen Cell type Surgical termination Medical termination Spontaneous
miscarriage
CB1 Syncytiotrophoblast
Cytotrophoblast
(Histoscore)
Mesenchymal core
(Histoscore)
Decidua
(Histoscore)
+/++
++
(161.0 ± 4.77)
-
(3.3 ± 0.40)
++
(66.6 ± 3.69)
+
+
(113.9 ± 7.48)
+
(15.5 ± 2.25)
++
(36.4 ± 5.57)
+
+
(79.8 ± 7.91)*
-
(8.8 ± 0.96)*
+
(15.0 ± 2.04)*
CB2 Syncytiotrophoblast
Cytotrophoblast
(Histoscore)
Mesenchymal core
(Histoscore)
Decidua
(Histoscore)
+
+
(96.5 ± 11.01)
-/+
(9.0 ± 1.96)
+
(14.8 ±1.59)
+/++
+
(114.3 ± 16.40)
-/+
(14.3 ± 2.4)
+/++
(68.8 ± 8.04)
++
++
(233.5 ± 5.27)*
++
(223.5 ± 5.27)**
+/++
(78.7 ± 6.06)
ns
NAPE-PLD Syncytiotrophoblast
Cytotrophoblast
(Histoscore)
Mesenchymal core
(Histoscore)
Decidua
(Histoscore)
-/+
+
(9.4 ± 2.77)
-
(1.7 ± 0.56)
-/+
(4.9 ± 0.51)
+/++
+
(32.0 ± 2.45)
-
(2.0 ± 0.23)
+
(11.2 ± 1.62)
-/+
+/++
(14.2 ± 2.68)
ns
-
(1.3 ± 0.38)
ns
-/+
(4.6 ± 0.69)*
FAAH Syncytiotrophoblast
Cytotrophoblast
(Histoscore)
Mesenchymal core
(Histoscore)
Decidua
(Histoscore)
+
-/+
(45.5 ± 7.08)
++
(42.0 ± 6.02)
+
(13.9 ± 2.34)
+/++
++
(127.8 ± 6.26)
+
(22.7 ± 5.03)
-/+
(23.2 ± 6.38)
+
+
(105.2 ± 7.74)
ns
-
(2.6 ± 0.59)*
++
(55.3 ± 4.00)**
Scoring system: (-) = absent; (+) = staining visible; (-/+) = staining occasionally absent;
(++) = stronger staining. The histoscore value for each antigen is shown as (mean ± sem) under each tissue that it represents. Each histoscore consists of 10
random fields/slide, for 10 matched samples each of surgical termination, medical abortion and spontaneous miscarriages taken from weeks 7 and 8 of gestation,
as described in the Materials & Methods section. Data in bold are significantly different to respective surgical termination tissue and *P<0.01;**P<0.001; One-way
ANOVA with Bonferroni’s ad hoc post-test when compared to the medical abortion group.
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Figure 1 Antibody specificity. The CB1, CB2, NAPE-PLD and FAAH antibodies demonstrated specific staining to first trimester trophoblast. CB1
specific staining was visible in the syncytiotrophoblast (sy), cytotrophoblast (ct) and fibroblast (f) cell cytoplasm and to a lower intensity in the
cytoplasm of the fetal endothelial cell (ec). Perinuclear and nuclear CB1 immunoreactivity was also observed in the cytotrophoblast layer, but
only in the occasional syncytiotrophoblast (sy). CB2 immunoreactivity was also observed to be cytoplasmic, with immunopositive cells observed
within the fetal blood vessels (bv), whereas NAPE-PLD immunoreactivity appeared almost exclusively in the nuclei of immunoreactive cells. FAAH
immunoreactivity was both nuclear and cytoplasmic with differential expression of nuclear staining within the cytotrophoblastic layer.
Photomicrographs are representative images taken from surgical terminations at weeks 7 and 8 of gestation. All images were captured at 400×
magnification; bar = 50 μm. Respective rabbit IgG isotype or rabbit serum controls at equivalent concentrations are shown in the left panels.
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Figure 2 The effect of gestation on CB1 immunoreactivity. CB1 immunostaining is present throughout the first trimester in both the
trophoblast (upper panels) and decidua (lower panels). In the trophoblast, the majority of the staining was confined to the cytotrophoblast and
syncytiotrophoblast layers, whereas intense immunoreactivity was observed in the decaying endometrial glands (G) and decidualised stromal
fibroblasts (S) of the early decidua. By contrast, blood vessels (BV) had much lower staining intensities. Images were taken at 100× magnification
and are representative of samples taken for each of the gestational dates indicated. Bar = 50 μm.
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Figure 3 The effect of gestation on CB2 immunoreactivity. CB2 immunostaining is present throughout the first trimester in both the
trophoblast (upper panels) and decidua (lower panels). In the trophoblast, the majority of the staining was confined to the cytotrophoblast and
syncytiotrophoblast layers and infiltrating maternal plasma cells. Similar to the CB1 immunostaining, intense CB2 immunoreactivity was observed
in the decaying endometrial glands and decidualised stromal fibroblasts. The intensity of decidual cell staining increased and reach a peak
around week 10. By contrast blood vessels had much lower staining intensities. Images were taken at 100× magnification and are representative
of samples taken for each of the gestational dates indicated. Bar = 50 μm.
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Figure 4 The effect of gestation NAPE-PLD immunoreactivity. NAPE-PLD immunostaining is present throughout the first trimester in both
the trophoblast (upper panels) and decidua (lower panels). In the trophoblast, the majority of the staining was confined to the cytotrophoblast
and syncytiotrophoblast layers, with the staining being preferentially observed in the cytotrophoblast layer when compared to the
syncytiotrophoblast layer. Intense nuclear staining was occasionally observed in syncytial knots (SK) whilst only the occasional mesenchymal
fibroblast showed NAPE-PLD immunoreactivity. Intense immunoreactivity was observed in some of the decidualised stromal fibroblasts. The
intensity of decidual cell staining was variable and reached a maximum at week 10 but was essentially absent in the stromal fibroblast by week
12. Images were taken at 100× magnification. Bar = 50 μm.
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Page 10 of 18core of the developing villi and in infiltrating maternal
plasma cells (Figure 5), but not in the fetal cells (Figure
1). Immunoreactive FAAH was detected in all 1st trime-
ster syncytiotrophoblast and cytotrophoblast layers
between weeks 7 and 12 (Figure 5) and the intensity of
staining increased gradually in the syncytiotrophoblast
layer of surgical terminations between the 7th and the
10th week of gestation (Figure 5). By the 11th week,
FAAH immunoreactivity at the syncytiotrophoblast layer
had diminished to the point where it was barely detect-
able within large parts of the trophoblast, an effect that
persisted into the 12th week (Figure 5).
Comparison of the CB1, CB2, FAAH and NAPE-PLD
staining patterns in tissues from medical terminations
and spontaneous miscarriages showed that CB1 expres-
sion in the trophoblast layer decreased in both types of
tissue when compared to that from surgical termina-
tions (Figure 6; Table 4). By contrast, CB2 immunoreac-
tivity increased in tissues from medical terminations and
significantly more so in the tissues from the sponta-
neous miscarriage group (Figure 6; Table 4). NAPE-PLD
immunoreactivity was primarily observed in the nucleus
of the cytotrophoblast of the surgical termination group.
Within the medical termination group, NAPE-PLD
immunoreactivity was not only observed in the nucleus
of the cytotrophoblast, but also in the syncytiotropho-
blast and in the stromal fibroblasts of the villi (Figure 6;
Table 4). NAPE-PLD staining was similarly present in
the cytotrophoblast and syncytiotrophoblast layers in
the spontaneous miscarriage group, but not in the stro-
mal fibroblasts. The levels of immunoreactive FAAH in
the cytotrophoblast layers were significantly increased in
both the medical termination and spontaneous miscar-
riage groups, with a more diffuse cytoplasmic staining
pattern observed in the syncytiotrophoblast layer of the
miscarriage samples when compared to the surgical ter-
mination samples (Figure 6; Table 4).
Cannabinoid receptor and AEA modifying enzyme
expression in the decidua
CB1 immunoreactivity was observed in the decidua
throughout the first trimester surgical termination sam-
ples, with little or no modulation from weeks 7 to 12
(Figure 2). Within the decidual cell, CB1 immunoreac-
tivity was observed primarily within the cytoplasm and
plasma membrane and was absent from the nucleus of
most cells (Figure 2). The staining was variable and ‘pat-
chy’ with clusters of decidual cells demonstrating similar
staining intensities that differed from adjacent areas of
decidua (Figure 2). In the endothelial cells of larger
capillaries, CB1 immunoreactivity was also observed in
the nucleus.
CB2 immunoreactive protein was also observed in the
surgical termination samples, but at a much lower level
when compared to CB1 immunoreactivity (Figure 3). As
was observed for CB1 immunoreactivity, CB2 immunor-
eactivity was also observed primarily within the cyto-
plasm and plasma membrane and was absent from the
nucleus of most cells. It was also absent from endothe-
lial cells of the larger capillaries (Figure 3). CB2 immu-
noreactivity gradually increased in the decidual cell
during the first trimester (Figure 3) with the greatest
immunoreactivity observed in weeks 9/10 of gestation.
NAPE-PLD immunoreactivity was observed in the
decidua throughout the first trimester, although the
staining was not uniformly distributed (Figure 4). In line
with the CB1 staining pattern in the decidual cells,
NAPE-PLD immunoreactivity was variable and ‘patchy’
with clusters of decidual cells demonstrating similar
staining intensities that differed from adjacent areas of
decidua (Figure 4). Where the decidual cell was immu-
nopositive, intense nuclear staining was observed. The
endothelial cells were also immunopositive demonstrat-
ing nuclear staining (Figure 4).
FAAH immunoreactivity was observed in the decidua
at levels equivalent to that observed for CB2 immunor-
eactivity (Figure 5). Staining in the decidual cell was
located in the cytoplasm and occasionally observed in
the nucleus. The cells surrounding the larger capillaries
showed a similar level of FAAH immunoreactivity in the
cytoplasm, whilst endothelial cells appeared to be immu-
nonegative (Figure 5). The expression of FAAH in the
first trimester decidua gradually increased reaching a
peak at weeks 9/10 (Figure 5).
Comparison of the CB1, CB2, FAAH and NAPE-PLD
staining patterns of medical terminations and sponta-
neous miscarriages indicated that CB1 expression in the
decidua increased in individual cells of the medical ter-
minations, but decreased in the spontaneous miscarriage
group (Figure 7; Table 4). Histoscore analyses indicated
that CB1 immunoreactivity decreased in both the medi-
cal termination and spontaneous miscarriage groups
(Table 4). By contrast, CB2 immunoreactivity increased
in the deciduas of both the medical termination and in
the spontaneous miscarriage samples (Figure 7; Table 4)
similar to that observed in the equivalent trophoblast
(Figure 6; Table 4). The levels of immunoreactive FAAH
were significantly increased in the spontaneous miscar-
riage group but not in the medical termination group,
with a more diffuse cytoplasmic staining pattern
observed in the medical termination deciduas when
compared to the surgical terminations, whilst there was
clear nuclear staining in the spontaneous miscarriage
group (Figure 7; Table 4). NAPE-PLD immunoreactivity
was increased in both the medical termination and in
the spontaneous miscarriage groups, with more intense
nuclear NAPE-PLD observed in the medical termination
when compared to either the surgical termination or the
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Figure 5 The effect of gestation on FAAH immunoreactivity. FAAH immunostaining is present throughout the first trimester in both the
trophoblast (upper panels) and decidua (lower panels). In the trophoblast, the majority of the staining was confined to the cytotrophoblast and
syncytiotrophoblast layers, although significant immunoreactivity was observed in the mesenchymal core. The intensity of FAAH
immunoreactivity throughout the trophoblast diminished in weeks 11 and 12 of gestation. Intense immunoreactivity was observed in the
decidualised stromal fibroblasts and decaying endometrial glands. The intensity of decidual cell staining increased and reached a peak around
week 10 and was diminished by 12. Images were taken at 100× magnification. Bar = 50 μm.
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Page 12 of 18spontaneous miscarriage samples (Figure 7; Table 4).
There was no significant change in NAPE-PLD staining
levels in the spontaneous miscarriage tissue when com-
pared to the surgical termination group, except that
staining was exclusively nuclear in the spontaneous mis-
carriage group, whereas some weak cytoplasmic immu-
noreactivity was observed in the surgical termination
group (Figure 7; Table 4).
Discussion
This study demonstrates that plasma AEA levels are
elevated in women with non-viable first trimester
pregnancies when compared to the levels in confirmed
viable pregnancies. The levels in viable pregnancies
were similar to those previously reported by Maccar-
rone et al. [13] and our group [27,32] and also similar
to those reported in the luteal phase of the menstrual
cycle [32,33,42], affirming the suggestion that for suc-
cessful implantation, plasma AEA levels need to be
maintained at a low level during both the implanta-
tion window [42] and early pregnancy development
[12,32].
In the mouse, a significant fall in AEA and a rise in
FAAH are essential at the implantation site compared to
Surgical Medical Spontaneous
CB1
NAPE-PLD
CB2
FAAH
Figure 6 The effect of medical abortion and spontaneous miscarriage on the localisation of endocannabinoid system in first trimester
trophoblast. Images are representative of 60 surgical and 25 medical terminations, and 16 spontaneous miscarriages. Spontaneous abortion is
c h a r a c t e r i s e db yam a r k e dd e c r e a s ei nt h ee x p r e s s i o no fC B 1 ,i n c r e a s e dC B 2a nd FAAH expression, whilst NAPE-PLD expression is unaffected. By contrast,
medical termination of pregnancy is characterised by a small decrease in CB1 expression, a small increase in NAPE-PLD expression and a marked increase
in cytotrophoblastic FAAH expression that does not occur in spontaneous miscarriage, which is characterised by a marked decrease in mesenchymal
FAAH expression. Images were taken at 200× magnification. Bar = 50 μm. Surgical termination of pregnancy was used as the control condition.
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Page 13 of 18the inter-implantation site for successful implantation
and early pregnancy maintenance [18,20]. The observa-
tions of Maccarrone et al. [43] and Habayeb et al.[ 2 7 ]
suggest that in humans, peripheral mononuclear cell
FAAH levels and the levels of AEA behave in a similar
way to the local uterine endocannabinoid changes
reported in the mouse uterus [44]. The findings of
raised plasma AEA concentrations in non-viable preg-
nancies at the time of presentation suggests that an
aberration in the endocannabinoid system might have
occurred resulting in a disruption of the normal implan-
tation and developmental process of the fetal-maternal
interface, thus causing miscarriage. Precisely when this
might have occurred is uncertain but since the levels of
AEA in non-viable pregnancies are much lower than
those we reported in women presenting with a threa-
tened miscarriage and a viable pregnancy who subse-
quently miscarried [27], we believe that this may
represent the AEA level returning to a ‘baseline’ follow-
ing a peak at the time of fetal demise. The AEA levels
found in these women were close to those seen during
the follicular phase of the menstrual cycle [42,45] sug-
gesting a preparation for the recommencement of the
menstrual cycle.
Surgical Medical Spontaneous
CB1
NAPE-PLD
CB2
FAAH
Figure 7 The effect of medical abortion and spontaneous miscarriage on the localisation of the endocannabinoid system in first
trimester decidua. Images are representative of 60 surgical and 25 medical terminations, and 16 spontaneous miscarriages. Medical termination
of pregnancy is characterised by an increase in the expression of CB2 and NAPE-PLD protein whilst overall CB1 expression is decreased and
FAAH expression is unaffected. By contrast, spontaneous miscarriage is also characterised by a marked increase in CB2 and FAAH expression and
a decrease in CB1 expression that exceeds that of medical termination samples. Images were taken at 200× magnification. Bar = 50 μm. Surgical
termination of pregnancy was used as the control condition.
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Page 14 of 18Serum progesterone and b-hCG levels were similar to
those reported in the literature [1,3,5,9,46-48]. As
expected, serum progesterone levels were significantly
lower in the non-viable group. These levels have been
used to help in the diagnosis and management of failed
pregnancies and more recently, pregnancies of unknown
location [1,2,47-50]. Although median b-hCG levels
were 4.4 times higher in the viable group, this difference
was not statistically significant. Various studies have
reported similar observations [3,5,6,8] and it is thought
that the absence of significant differences is due largely
to variations in the timing of the sample collection. For
example, it is likely that some of our samples would
have been taken immediately after the pregnancy chan-
ged from a viable to non-viable state and in others they
would have been taken days later, when b-hCG levels
would have already fallen significantly. Furthermore, it is
known that as a predictor of pregnancy failure b-hCG is
poor, with a sensitivity and specificity of only around
80%, and wide variations have been seen between stu-
dies when defining a threshold level for viability at a
specific gestation [3].
The lack of a correlation between AEA and either
serum b-hCG or progesterone in the cohort as a whole
could easily be interpreted to mean that plasma AEA
levels are linked to early pregnancy failure through a
mechanism independent of these factors. The lack of a
correlation between AEA and progesterone, however, is
at odds with the suggestion of Maccarrone et al., that
low P4 levels were associated with high plasma AEA
levels, through a mechanism that involves the direct sti-
mulation of FAAH (the main enzyme that degrades
AEA) in peripheral mononuclear cells [13,29] and so we
were therefore surprised by the lack of correlation
between P4 and AEA levels in the present study,
although a larger sample could possibly demonstrate the
significant correlation we anticipated. At present, it is
not clear how rapidly the levels of these biomarkers
return to normal after miscarriage and if, as may be the
case, one biomarker is cleared faster than the other, a
previously existing correlation may thus be absent.
Therefore, by combining the viable and non-viable
groups to perform the correlations, we might have inad-
vertently hidden any correlations in the viable data and
vice versa. Re-examining our data under the discrete
groups of viable and non-viable pregnancies (Table 3)
then revealed an almost significant negative correlation
between AEA and b-hCG in the viable group and a sig-
nificant correlation between b-hCG and P4 only in the
non-viable group as would be expected based on pub-
lished literature [9,51,52]. The serum levels of progester-
one and PAPP-A were perfectly correlated, although the
number of samples assayed was relatively small. There
was also a correlation between plasma AEA levels and
PAPP-A levels, but only in the non-viable pregnancies
and a negative correlation between length of gestation
and plasma AEA levels in the non-viable group, but not
in the viable group.
A third possibility to explain the apparent discrepan-
cies in the correlation analyses is the possibility that
genetic abnormalities in the fetus may alter the expres-
sion of the enzymes controlling the levels of these bio-
markers. Nevertheless, these data suggest that a
complex interplay is involved between these factors and
early pregnancy success.
Although PAPP-A levels were increased in the non-
viable group these values did not reach statistical signifi-
cance. A decrease in PAPP-A levels is now considered
to be a marker of problems in pregnancy [6,8], and this
discrepancy may be due to small numbers involved
( b e c a u s es o m em e a s u r e m e n t sw e r eb e l o wt h el i m i to f
detection and so did not contribute to the analysis), or
due to the fact that the pregnancies had already failed
[53-55]. There was, however, a strong correlation
between P4, b-hCG and PAPP-A levels in both viable
and non-viable pregnancies, suggesting a causal link in
the production of each of these factors. At present, the
factors involved in the production of PAPP-A are
unclear and although a number of factors have been
implicated in its generation, P4 is not one of them
[6,8,56]. The positive correlation between AEA and
PAPP-A might also indicate a causal link between these
two factors. There are two main possibilities here.
Firstly, there is a pregnancy ‘master regulator’ that con-
trols the expression of both AEA and PAPP-A, or sec-
ondly, that these two factors regulate each other.
Currently, there is insufficient data to support either of
these possibilities.
The finding of an association between raised plasma
AEA and non-viable pregnancies could mean either that
either a disruption in the endocannabinoid system led
to a disruption of the normal implantation and develop-
mental process, causing miscarriage or that a failed
pregnancy, for whatever reason, is associated with a dis-
ruption in the endocannabinoid system in favour of a
higher AEA level. Which of these possibilities is the
more likely is uncertain. By investigating the expression
patterns of the endocannabinoid system in the tropho-
blast and decidua, we hoped to further elaborate on
some of these possibilities.
Although the trophoblast, the endometrium, and the
embryo all contain CB1 and CB2 receptors, NAPE-PLD
and FAAH, we are inclined to conclude that the tropho-
blast appears not to be the main target for the action of
AEA in early pregnancy failure due to the lack of corre-
lation between the levels of AEA and either b-hCG, P4
and PAPP-A. During early pregnancy, the placenta par-
ticipates in the production of these three hormones and
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Page 15 of 18if AEA was having a detrimental effect on the develop-
ing trophoblast, then the levels of these hormones
would be expected to be inversely modulated in relation
to AEA levels. Furthermore, it would be anticipated that
the plasma AEA levels would also be reflected at the
local level by alterations in the expression of the AEA
modulating enzymes NAPE-PLD and FAAH, such that
either NAPE-PLD levels increased, whilst FAAH levels
decreased or remained constant [57], or NAPE-PLD
levels remain constant along with decreased FAAH
levels. Such changes would thus cause the local AEA
concentrations to increase. The staining patterns for
these two enzymes actually showed that NAPE-PLD
remained constant, whilst FAAH levels increased. These
changes would result in decreased local AEA levels in
the placenta should the enzymes be fully activated. The
nuclear localisation of NAPE-PLD in trophoblast and in
the decidua was surprise as AEA is variously reported as
being synthesised ‘on-demand’ from membrane precur-
sors and as such is considered to be an integral compo-
nent of the plasma membrane [14,15]. The possibilities
here are that (a) the NAPE-PLD protein identified by
this antibody is inactive because it is localised in the
nucleus, (b) that synthesised AEA is not made ‘on-
demand’, but is made and sequestered within the cell, or
(c) the NAPE-PLD antibody used in this study is not
specific for NAPE-PLD and detects an alternative pro-
tein. The first possibility was not tested in this study
and could still be correct, the second possibility is sup-
ported by recent evidence that AEA (being highly lipo-
philic) is transported around the cell on fatty acid
binding proteins [58,59] and so AEA could be synthe-
sised in sites other than the plasma membrane and
store in adiposomes and the third possibility could also
be true in that the antibody used does not detect the
NAPE-PLD protein but some other irrelevant protein,
but is unlikely, since we have recently demonstrated
nuclear staining of NAPE-PLD in the rat placenta and
decidua using a different source of NAPE-PLD antibody
[60,61], suggesting that, in the pregnant uterus at least,
NAPE-PLD protein is located in the nucleus. Similar
nuclear NAPE-PLD staining was observed in the normal
menstrual cycle and in the normal human ovary sug-
gesting that NAPE-PLD is indeed expressed in the
nucleus [31,36].
In contrast to the static expression of NAPE-PLD and
increased expression of FAAH, there were reciprocal
expressions of CB1 and CB2 in the trophoblast during
the transition from the viable to non-viable state [62],
with CB2 expression increasing in the trophoblast.
These data suggest that AEA signalling through tropho-
blastic CB2 could mediate trophoblast demise similar to
the effect that Δ
9-tetrahydrocannabinol has on human
trophoblast cell lines, again through the CB2 receptor
[63]. Recent immunohistological staining patterns for
CB1, CB2, FAAH, NAPE-PLD and the 2-AG modulating
enzymes, MAGL and DAGL show similar patterns of
expression in the mature rat placenta, with decreased
CB1 expression at the end of gestation (unpublished
observations). These data, with those of Acone et al.,
[57] are supportive of reduced CB1 signalling and
increased FAAH expression in the placenta as being
important not only in spontaneous and recurrent mis-
carriage [39], but also in the process of labour, at the
end of pregnancy [57].
Furthermore, the increased expression of CB1 in the
decidua of medical terminations and spontaneous mis-
carriages is totally in keeping with the recent evidence
that modulation of CB1 receptor expression in the rat
decidua occurs naturally and AEA induces apoptosis in
the decidua through this receptor isoform [60,64]. Addi-
tionally, the demonstration that AEA modifying enzyme
distribution in the decidua changes to support local
accumulation of anandamide, i.e. NAPE-PLD expression
similar to that found in the rat [61] suggest that AEA
acts at the level of the local endometrial-embryo inter-
face in the human too, and therefore primarily on the
decidua. These data suggest that the decidua is the main
target for AEA action during early pregnancy, although
the trophoblast may also be a target.
Conclusions
Our data confirm that there is an interaction between
the components of the endocannabinoid system and the
fetal-maternal interface and we believe that further stu-
dies of this interaction may eventually lead to the identi-
fication of potential areas for intervention to reduce the
incidence of spontaneous miscarriages or new therapeu-
tics for pregnancy termination.
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